BMS-986218 + Nivolumab for Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing whether a new drug, BMS-986218, alone or with Nivolumab, is safe for patients with advanced solid tumors. These drugs help the immune system fight cancer. Nivolumab is a treatment that has been used for various cancers, including melanoma, lung cancer, and renal cell carcinoma.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it mentions that at least 4 weeks must pass since your last dose of certain anti-cancer therapies before starting the study treatment.
What data supports the effectiveness of the drug combination BMS-986218 and Nivolumab for cancer?
Is the combination of BMS-986218 and Nivolumab safe for humans?
Nivolumab, also known as Opdivo, has been studied in various cancers and is generally considered safe, with manageable side effects, including immune-related reactions. It has been used in combination with other drugs like Ipilimumab (Yervoy) and has shown a tolerable safety profile in patients with advanced cancers.12467
What makes the drug combination of BMS-986218 and Nivolumab unique for cancer treatment?
The combination of BMS-986218 and Nivolumab is unique because BMS-986218 is an OX40 agonist that can enhance the immune system's response to cancer, while Nivolumab is a PD-1 inhibitor that helps the immune system recognize and attack cancer cells. This dual approach aims to boost the body's natural defenses against tumors more effectively than using either drug alone.12348
Research Team
Bristol Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
This trial is for adults with advanced solid tumors who've tried at least two standard treatments without success. It's open to those with specific cancers like melanoma, lung cancer, and colorectal cancer that haven't spread to the brain. Participants should be fairly active and healthy otherwise (with a performance status of 0 or 1).Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986218 alone or in combination with Nivolumab to assess safety and tolerability in advanced solid tumors
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BMS-986218
- Ipilimumab
- Nivolumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania